NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.08. During the same period in the prior year, the company earned ($0.24) EPS. View Spectrum Pharmaceuticals' Earnings History.

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 brokers have issued 12 month target prices for Spectrum Pharmaceuticals' stock. Their forecasts range from $4.00 to $21.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $13.20 in the next twelve months. This suggests a possible upside of 334.2% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

News articles about SPPI stock have been trending very positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a news sentiment score of 3.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 13,050,000 shares, an increase of 13.9% from the January 15th total of 11,460,000 shares. Based on an average trading volume of 2,311,200 shares, the short-interest ratio is presently 5.6 days. Currently, 13.3% of the shares of the company are short sold. View Spectrum Pharmaceuticals' Current Options Chain.

Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Amicus Therapeutics (FOLD), Verastem (VSTM), Bausch Health Companies (BHC) and AT&T (T).

Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.29%), Renaissance Technologies LLC (2.48%), Geode Capital Management LLC (1.36%), FMR LLC (1.23%), Bank of New York Mellon Corp (1.12%) and ArrowMark Colorado Holdings LLC (0.95%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

SPPI stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, Sargent Investment Group LLC, Sargent Investment Group LLC, Panagora Asset Management Inc., Citigroup Inc., UBS Group AG and Arizona State Retirement System. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Insider Buying and Selling for Spectrum Pharmaceuticals.

SPPI stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Alpine Global Management LLC, Great West Life Assurance Co. Can, Geode Capital Management LLC, Bank of New York Mellon Corp and Teza Capital Management LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SPPI stock can currently be purchased for approximately $3.04.

Spectrum Pharmaceuticals has a market capitalization of $343.43 million and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.View Additional Information About Spectrum Pharmaceuticals.

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]